145 related articles for article (PubMed ID: 2606928)
1. Evidence of a role for NK cells in oxazaphosphorine-mediated tumor regression.
Reissmann T; Hilgard P; Voegeli R; Zeller J
J Cancer Res Clin Oncol; 1989; 115(6):525-30. PubMed ID: 2606928
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of host antitumor immunity by low doses of cyclophosphamide and mafosfamide in two animal tumor models.
Reissmann T; Voegeli R; Pohl J; Hilgard P
Cancer Immunol Immunother; 1989; 28(3):179-84. PubMed ID: 2924329
[TBL] [Abstract][Full Text] [Related]
3. Oxazaphosphorine effects in L 5222 rat leukemia.
Pohl J; Reissmann T; Voegeli R
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
[TBL] [Abstract][Full Text] [Related]
4. Immunoregulation of murine plasmacytoma. I. Generation of anomalous killer cells in vitro by cocultivation with MOPC 104E.
Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
Cancer Invest; 1989; 7(1):17-26. PubMed ID: 2567619
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
6. In vitro NK-activity and in vivo resistance to leukemia: studies of beige, beige//nude and wild-type hosts on C57BL background.
Kärre K; Klein GO; Kiessling R; Klein G; Roder JC
Int J Cancer; 1980 Dec; 26(6):789-97. PubMed ID: 7216547
[TBL] [Abstract][Full Text] [Related]
7. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
8. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors.
Atassi G; Hilgard P; Pohl J
Invest New Drugs; 1984; 2(2):169-73. PubMed ID: 6469511
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mouse natural killer activity by cyclosporin A.
Yanagihara RH; Adler WH
Immunology; 1982 Feb; 45(2):325-32. PubMed ID: 6460686
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of augmentation of natural killer cell activity by syngeneic tumor cells: role of macrophage-derived factor in NK boosting.
Kawase I; Urdal DL; Newman W; Henney CS
Int J Cancer; 1983 Mar; 31(3):365-72. PubMed ID: 6402456
[TBL] [Abstract][Full Text] [Related]
12. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
13. Role of natural killer cells in control of cancer metastasis.
Hanna N
Cancer Metastasis Rev; 1982; 1(1):45-64. PubMed ID: 7185419
[TBL] [Abstract][Full Text] [Related]
14. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
Mokyr MB; Dray S
Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
[TBL] [Abstract][Full Text] [Related]
15. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
16. Role of natural killer cells in the destruction of circulating tumor emboli.
Hanna N; Fidler IJ
J Natl Cancer Inst; 1980 Oct; 65(4):801-9. PubMed ID: 6932529
[TBL] [Abstract][Full Text] [Related]
17. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.
Gorelik E; Wiltrout RH; Okumura K; Habu S; Herberman RB
Int J Cancer; 1982 Jul; 30(1):107-12. PubMed ID: 7118294
[TBL] [Abstract][Full Text] [Related]
18. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
19. Increase in immunogenicity and sensitivity to natural cell-mediated cytotoxicity following in vitro exposure of MCA105 tumor cells to ultraviolet radiation.
Begovic M; Herberman R; Gorelik E
Cancer Res; 1991 Oct; 51(19):5153-9. PubMed ID: 1913641
[TBL] [Abstract][Full Text] [Related]
20. An experimental model for meningeal leukemia in rats (L5222). Effect of treatment with BCNU and cyclophosphamide.
Fiebig HH; Zeller WH; Schmähl D
Int J Cancer; 1976 Nov; 18(5):710-6. PubMed ID: 992902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
